Department of Central Laboratory, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China.
Department of Hematology, The Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China.
Cancer Gene Ther. 2021 Dec;28(12):1256-1268. doi: 10.1038/s41417-020-00291-4. Epub 2021 Jan 5.
Multiple myeloma (MM) is a malignant disease of plasma cells with complex pathology, causing significant morbidity due to its end-organ destruction. The outcomes of patients with myeloma have significantly improved in the past couple of decades with the introduction of novel agents, such as proteasome inhibitors, immunomodulators, and monoclonal antibodies. However, MM remains incurable and presents considerable individual heterogeneity. MicroRNAs (miRNAs) are short, endogenous noncoding RNAs of 19-22 nucleotides that regulate gene expression at the posttranscriptional level. Numerous studies have shown that miRNA deregulation is closely related to MM pathology, including tumor initiation, progression, metastasis, prognosis, and drug response, which make the complicated miRNA network an attractive and marvelous area of investigation for novel anti-MM therapeutic approaches. Herein, we mainly summarized the current knowledge on the roles of miRNAs, which are of great significance in regulating pathological factors involved in MM progressions, such as bone marrow microenvironment, methylation, immune regulation, genomic instability, and drug resistance. Meanwhile, their potential as novel prognostic biomarkers and therapeutic targets was also discussed.
多发性骨髓瘤(MM)是一种浆细胞恶性疾病,具有复杂的病理学特征,由于其终末器官破坏而导致发病率较高。在过去几十年中,随着新型药物如蛋白酶体抑制剂、免疫调节剂和单克隆抗体的引入,骨髓瘤患者的预后得到了显著改善。然而,MM 仍然无法治愈,并且存在很大的个体异质性。微小 RNA(miRNA)是一种 19-22 个核苷酸的短内源性非编码 RNA,可在转录后水平调节基因表达。大量研究表明,miRNA 失调与 MM 病理学密切相关,包括肿瘤起始、进展、转移、预后和药物反应,这使得复杂的 miRNA 网络成为新型抗 MM 治疗方法的一个有吸引力和奇妙的研究领域。在此,我们主要总结了 miRNA 在调节 MM 进展中涉及的病理因素(如骨髓微环境、甲基化、免疫调节、基因组不稳定性和耐药性)中的作用的现有知识。同时,还讨论了它们作为新型预后生物标志物和治疗靶点的潜力。